Jeffrey M. Saland

Icahn School of Medicine at Mount Sinai — United States

Medicine · Health Sciences

33h-index3.7kcitations81works5.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Kidney Stones and Urolithiasis Treatments(15), Dialysis and Renal Disease Management(10), Chronic Kidney Disease and Diabetes(9), Complement system in diseases(9), Porphyrin Metabolism and Disorders(8)

Publications81 total

Final Results of the ILLUMINATE-A Phase 3 Clinical Trial of Lumasiran for Primary Hyperoxaluria 1
Clinical Journal of the American Society of Nephrology·2025Open Access
Cytokine-Driven Janus Kinase Signal Transducer and Activator of Transcription Pathway Hyperactivity Predicts Disease Severity in Pediatric FSGS
Kidney360·2025Open Access
PD33-02 LONG-TERM EFFECTS OF LUMASIRAN ON KIDNEY STONES AND NEPHROCALCINOSIS IN PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1
The Journal of Urology·2025
Long-Term Efficacy and Safety of Lumasiran in Patients with Primary Hyperoxaluria Type 1: Final Analysis of the ILLUMINATE-A Trial
Journal of the American Society of Nephrology·2024
Diagnosis and management of primary hyperoxalurias: best practices
Pediatric Nephrology·2024· 18 cited
Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Results from a Phase III Clinical Trial
Kidney International Reports·2024· 14 citedOpen Access
Tofacitinib Suppresses JAK/STAT Pathway Hyperactivity Ex Vivo in Pediatric Focal Segmental Glomerulosclerosis
Journal of the American Society of Nephrology·2023
Updated consensus guidelines on the management of Phelan–McDermid syndrome
American Journal of Medical Genetics Part A·2023· 43 citedOpen Access
Development of an adaptive clinical web-based prediction tool for kidney replacement therapy in children with chronic kidney disease
Kidney International·2023· 9 citedOpen Access
MP10-01 EFFICACY AND SAFETY OF LUMASIRAN IN PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1: 36-MONTH ANALYSIS OF THE ILLUMINATE-A TRIAL
The Journal of Urology·2023
Revisiting the Application of an Adult Kidney Failure Risk Prediction Equation to Children With CKD
American Journal of Kidney Diseases·2022· 4 citedOpen Access
Blood Pressure Classification Status in Children With CKD Following Adoption of the 2017 American Academy of Pediatrics Guideline
American Journal of Kidney Diseases·2022· 2 citedOpen Access
Aberrant JAK/STAT Signaling in Nephrotic Syndrome
Journal of the American Society of Nephrology·2022
Efficacité et sécurité du Lumasiran chez les patients atteints d’hyperoxalurie primaire de type 1 : analyse à 24 mois de l’essai ILLUMINATE-A
Néphrologie & Thérapeutique·2022
PD05-03 EFFICACY AND SAFETY OF LUMASIRAN IN PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1: 24-MONTH ANALYSIS OF THE ILLUMINATE-A TRIAL
The Journal of Urology·2022
Self-reported Race, Serum Creatinine, Cystatin C, and GFR in Children and Young Adults With Pediatric Kidney Diseases: A Report From the Chronic Kidney Disease in Children (CKiD) Study
American Journal of Kidney Diseases·2021· 14 citedOpen Access
Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1
Kidney International Reports·2021· 29 citedOpen Access
Effets du lumasiran sur les calculs rénaux et la néphrocalcinose chez les patients atteints d’hyperoxalurie primitive de type 1
Néphrologie & Thérapeutique·2021
Analyse à 12 mois d’ILLUMINATE-A, une étude de phase 3 du lumasiran : réduction durable de l’oxalate et des taux d’évènements de calculs rénaux dans l’hyperoxalurie primitive de type 1
Néphrologie & Thérapeutique·2021
MP07-08 EFFECT OF LUMASIRAN ON KIDNEY STONES AND NEPHROCALCINOSIS IN PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1
The Journal of Urology·2021Open Access
page 1 of 5Next →

Frequent Co-authors

Susan L. Furth(19), Bradley A. Warady(18), Joseph T. Flynn(11), Mark Mitsnefes(10), Randall Jenkins(9), George J. Schwartz(8), Joshua Samuels(7), Tom Blydt‐Hansen(7), Larry A. Greenbaum(7), Yaacov Frishberg(6), Craig S. Wong(6), Frederick J. Kaskel(6), Robert H. Mak(6), Hadas Shasha‐Lavsky(5), Daniella Magen(5), Shabbir H. Moochhala(5), Eva Šimková(5), Jaap W. Groothoff(5), David J. Sas(5), John M. Gansner(5)